-
12:35:26 PM

UCBJY Stock News

07/21/23 7:00 AM
OTC : UCBJY
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
RYSTIGGO is now commercially available by prescription in the United States for adult patients with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive 1 RYSTIGGO is the first and only FDA-approved targeted treatment for both anti-AChR Ab+ and anti-MuSK Ab+ adults with gMG 1 ONWARD™, a personalized patient...
RHEA-AI
neutral
06/27/23 7:00 AM
OTC : UCBJY
fda approval
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
FDA approval of RYSTIGGO ® has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive 1 U.S. FDA approval is based on the pivotal Phase 3 MycarinG study in gMG 2, a large phase 3 study which...
RHEA-AI
neutral
04/17/23 7:14 AM
OTC : UCBJY
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
UCB, a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration has published a final rule stating that FINTEPLA oral solution is no longer subject to the Controlled Substances Act. "We are pleased that FINTEPLA, which has a unique mechanism of action different from and complementary to other anti-seizure medications, has...
RHEA-AI
positive